Boston Scientific recently announced the acquisition of Obsidio. Obsidio is a privately held company that develops gel embolization material (GEM) technology for embolizing peripheral blood vessels.
Embolization is a minimally invasive procedure that blocks or reduces the blood supply to abnormal tissues and tumors. Its main role is to stop bleeding, reduce the volume of malignant or benign tumors, and improve vascular malformations.
The GEM technology recently approved by the US FDA is a semi-solid patented material. Its packaging is ready to use, which reduces the preparation time before embolization. The surgeon infuses the GEM through the catheter, and its gel texture allows it to be placed in the patient in a controlled manner. Different from solid or liquid embolic agents, the first two require a period of time to block blood vessels after injection; while GEM technology can immediately fit the target blood vessels and form a blood flow barrier immediately.
Peter Pattison, president of Interventional Oncology and Embolization, Boston Scientific's Peripheral Interventional Division, said: "GEM technology combines the advantages of current embolic agents, such as the precise controllability of solid embolic agents and the malleability of liquid embolic agents, to create a new A unique technology that brings greater surgical efficiency and more personalized treatment to patients. This acquisition further strengthens Poco's portfolio of interventional oncology and embolization therapy for physicians and patients with bleeding, cancer or other Debilitating patients offer differentiated solutions."
The transaction is not expected to have a material impact on Boston Scientific's 2022 GAAP and adjusted earnings per share. Specific terms of the deal were not disclosed.